RCS - BATM Advanced Comm - Appointment of CEO of ADOR Diagnostics

Batm Advanced CommunicationsAnnouncement

19/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220719:nRSS8780Sa&default-theme=true

RNS Number : 8780S  BATM Advanced Communications Ld  19 July 2022

LEI: 213800FLQUB9J289RU66

19 July 2022

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Appointment of CEO of ADOR Diagnostics

Bioscience expert appointed to lead advanced molecular diagnostics associate
company

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for
networking solutions and medical laboratory systems, is pleased to announce
the appointment of Dr. Eran Zahavy as CEO of ADOR Diagnostics ("ADOR"), the
Group's associate company that is developing the NATlab rapid molecular
diagnostics platform.

 

Dr. Eran Zahavy has more than 20 years' experience in leading positions in
government and private bio-science organisations. This includes roles such as
R&D manager for biological pathogens diagnostics and Head of Innovation at
the Israel Institute for Biological Research ("IIBR"). During the pandemic, at
IIBR he oversaw the development of the BriLife COVID-19 vaccine in
collaboration with US-based NRx Pharmaceuticals. Other roles have included
serving as CTO at Hutchison Kinrot, the operator of a technology incubator in
Israel and a seed investor in water and cleantech-related technologies; CTO of
TACount, a developer of imaging-based microbiological testing technology; and
as scientific advisor to Longliv Ventures, a strategic investor in health-tech
start-ups and part of the CK Hutchison Holdings Group.

 

For the last few years, Dr. Zahavy has served as CTO of the Group's
Bio-Medical Division and as Senior Scientific Consultant to ADOR and BATM's
Adaltis diagnostics subsidiary. During this time, he has been instrumental in
the progress made in the Group's molecular diagnostics activities.

 

Dr. Zahavy holds a PhD in Chemistry & Biophysics from the Hebrew
University and undertook a postdoc at the University of Texas, Austin and the
University of California, San Diego. He has more than 40 peer reviewed
scientific publications to his name as well as patents.

 

Dr. Zvi Marom, CEO of BATM, said: "We're pleased to have appointed Eran as
CEO of ADOR. He has an impressive track record of bioscience development and
has been critical to the fantastic progress that we have made in our
Bio-Medical Division in recent years. It is an exciting time for ADOR as we
move to the pre-production phase and towards becoming a commercial clinical
solution. We look forward to leveraging Eran's experience and expertise for
the next stage of development in ADOR."

 

ADOR is developing the NATlab system, which is a molecular diagnostics
platform that uses the isothermal amplification (RCA) process to provide rapid
sample-to-answer testing of pathogens. The NATlab instrument tests for
multiple pathogens using a single cartridge, with different cartridges being
designed for different infectious disease panels, such as meningitis,
respiratory diseases, STIs and more. The Group, through ADOR and Adaltis, is
also partnering with the Stop TB Partnership to develop a solution for the
rapid and comprehensive diagnosis of tuberculosis.

 

Dr. Eran Zahavy, CEO of ADOR Diagnostics, added: "I am excited to be taking up
this role with ADOR. We are paving a new path for the diagnosis of infectious
diseases. With a rapid diagnostics solution that can be operational at both
the point of care and in labs, we can enable the appropriate and immediate
treatment of disease, which is better for patients and for public health
authorities."

 

 

 

Enquiries:

 

 BATM Advanced Communications
 Dr Zvi Marom, Chief Executive Officer  +972 9866 2525
 Moti Nagar, Chief Financial Officer

 Luther Pendragon
 Harry Chathli, Claire Norbury          +44 20 7618 9100

 

 

 

Forward-looking statements

 

This document contains forward-looking statements. Those statements reflect
the current opinions, evaluations and estimations of the Group's management,
and are based on the current data regarding the Group's business as is
detailed in this document and in the Group's periodical, interim and immediate
reports. The Group does not undertake any obligation or make any
representation that actual results and events will be in line with those
statements, and stresses that they may differ materially from those
statements, due to changes in the Group's business, market, competition,
demand for the Group's products or services, general economic factors or other
factors that can influence the Group's business and results, and due to
information and factors that are currently unknown to the Group's management
and that, if known, would affect the management's opinions, evaluations or
estimations. The Group will report the actual results and events according to
its legal, accounting and regulatory obligations, and does not undertake any
other obligation to report them or their deviations from the forward-looking
statements, or to update any of the forward-looking statements in this
document or to report that it is not valid anymore.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLGDRGXBDGDI